Table of Contents
Volume 2011 (2011), Article ID 150750, 6 pages
Research Article

Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement

1Department of Orthopaedics, Århus University Hospital, Nørrebrogade 44, 8000 Århus C, Denmark
2Neonatalklinikken GN5023, Rigshospitalet, Blegdamsvej 9, 2100 København, Denmark
3Department of Orthopaedics, Nordsjællands Hospital Hørsholm, Usserød Kongevej 102, 2970 Hørsholm, Denmark
4Bayer HealthCare AG, Aprather Weg 18a, 42096 Wuppertal, Germany

Received 12 November 2010; Accepted 16 February 2011

Academic Editor: David H. Farrell

Copyright © 2011 Lars C. Borris et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prothrombin fragment 1+2 is excreted in urine (uF1+2) as a result of in vivo thrombin generation and can be a marker of coagulation status after an operative procedure. This study compared uF1+2 levels in patients with symptomatic and non-symptomatic venous thromboembolism (VTE) after total knee replacement (TKR) and in event-free sex- and age-matched controls. Significantly higher median uF1+2 levels were seen in the VTE patients on days 1, 3, and the day of venography (mostly day 7) after TKR compared with controls. The uF1+2 levels tended to be high in some patients with symptomatic VTE; however, the discriminatory efficacy of the test could not be evaluated. In conclusion, this study showed that patients with VTE tend to have significantly higher uF1+2 levels compared with patients without events between days 1 and 7 after TKR surgery. Measurement of uF1+2 could provide a simple, non-invasive clinical test to identify patients at risk of VTE.